

(12) PATENT		(11) Application No. AU 199671887 B2				
(19) AUSTRALIAN PATENT OFFICE		(10) Patent No. 706122				
<p>(54) Title Mycobacterium vaccae for treatment of long term autoimmune conditions</p> <p>(51)⁶ International Patent Classification(s) A61K 039/04</p> <p>(21) Application No: 199671887 (22) Application Date: 1996.11.20</p> <p>(30) Priority Data</p> <table> <tr> <td>(31) Number 9203814</td> <td>(32) Date 1992.02.21</td> <td>(33) Country GB</td> </tr> </table> <p>(43) Publication Date : 1997.02.06 (43) Publication Journal Date : 1997.02.06 (44) Accepted Journal Date : 1999.06.10</p> <p>(62) Divisional of: 199336377</p> <p>(71) Applicant(s) University College London</p> <p>(72) Inventor(s) John Lawson Stanford; Graham Arthur William Rook</p> <p>(74) Agent/Attorney DAVIES COLLISON CAVE, 1 Little Collins Street, MELBOURNE VIC 3000</p> <p>(56) Related Art WO 91/02542 WO 85/05034 AU 88741/91</p>				(31) Number 9203814	(32) Date 1992.02.21	(33) Country GB
(31) Number 9203814	(32) Date 1992.02.21	(33) Country GB				

BEST AVAILABLE COPY



AU9671887

(12) PATENT ABSTRACT (11) Document No. AU-A-71887/96
(19) AUSTRALIAN PATENT OFFICE

- (54) Title
MYCOBACTERIUM VACCAE FOR TREATMENT OF LONG TERM AUTOIMMUNE CONDITIONS
International Patent Classification(s)
(51)⁶ A61K 039/04
- (21) Application No. : 71887/96 (22) Application Date : 20.11.96
- (30) Priority Data
- (31) Number (32) Date (33) Country
9203814 21.02.92 GB UNITED KINGDOM
- (43) Publication Date : 06.02.97
- (62) Related to Division(s) : 36977/93
- (71) Applicant(s)
UNIVERSITY COLLEGE LONDON
- (72) Inventor(s)
JOHN LAWSON STANFORD; GRAHAM ARTHUR WILLIAM ROOK
- (74) Attorney or Agent
DAVIES COLLISON CAVE, 1 Little Collins Street, MELBOURNE VIC 3000
- (57) Claim
1. A method for the prophylaxis or treatment of vascular diseases or complications which are immunologically mediated including those associated with tuberculosis or diabetes which comprises administering to the patient suffering from such a condition an effective amount of antigenic and/or immunoregulatory material derived from *Mycobacterium vaccae*.
7. A product comprising antigenic and/or immunoregulatory material derived from *Mycobacterium vaccae* when used in the prophylaxis or treatment of vascular diseases or complications which are immunologically mediated including those associated with tuberculosis or diabetes.
9. A pharmaceutical agent when used in the prophylaxis or treatment of vascular diseases or complications which are immunologically mediated including those associated with tuberculosis or diabetes which agent comprises antigenic and/or immunoregulatory material derived from *Mycobacterium vaccae*.

AUSTRALIA
PATENTS ACT 1990

ORIGINAL
COMPLETE SPECIFICATION

Name of Applicant: University College London
Address of Applicant: Gower Street, London WC1E 6BT, United Kingdom

Actual Inventor(s): John Lawson Stanford; Graham Arthur William Rook.

Address for Service: DAVIES COLLISON CAVE, Patent Attorneys,
1 Little Collins Street, Melbourne Victoria 3000.
Australia

Complete Specification for the invention entitled:

Mycobacterium vaccae for treatment of long term autoimmune conditions

The following statement is a full description of this invention, including the best method
of performing it known to us:

MYCOBACTERIUM VACCAE FOR TREATMENT OF LONG TERM AUTOIMMUNE CONDITIONS

This invention relates to the treatment of mental diseases associated with an autoimmune reaction initiated by an infection, and of the auto-immunologically mediated consequences (other than uveitis) of chronic infections.

British Specification No. 2156673 describes immunotherapeutic agents comprising killed cells of *Mycobacterium vaccae*. These agents are useful in the immunotherapy of mycobacterial disease, especially tuberculosis and leprosy. It is stated that use of this immunotherapeutic agent facilitates the removal of the persisting bacilli responsible for tuberculosis or leprosy which, as is well known, it is difficult to remove by chemotherapy alone. It is suggested in the specification that the immunotherapeutic agent is believed to act by presenting the "protective" common mycobacterial antigens to advantage and by containing immune suppressor determinants which are active in regulating disadvantageous immune mechanisms. As a consequence, "persistor" bacilli are recognised by the immune system by their content of common mycobacterial antigens and effective immune mechanisms are directed against them, in the absence of the tissue necrotic form of immunity usually present in mycobacterial disease.

International Patent Specification PCT/GB85/00183 describes compositions for the alleviation of the symptoms of, and for the treatment or diagnosis of, arthritic diseases which comprise as active ingredient the whole organism of *M. vaccae*. It is stated that the preparations of *M. vaccae* are useful for the treatment of various autoimmune diseases and especially

arthritic conditions including rheumatoid arthritis, ankylosing spondylitis or Reiter's syndrome.

International Patent Specification PCT/GB90/01318 discloses that compositions which comprise M. vaccae as active ingredient are useful in the treatment of other pathological conditions in which the patient shows an abnormally high proportion of agalactosyl IgG and also in the treatment of chronic inflammatory disorders caused or accompanied by an abnormally high release by macrophages of interleukin-6 and/or 10 tumour necrosis factor. The specification refers in particular to the treatment of Crohn's disease, reactive arthritis, primary biliary cirrhosis, sarcoidosis, ulcerative colitis, psoriasis, systemic lupus erythematosus (especially when accompanied by Sjogren's syndrome), multiple sclerosis, 15 Guillain-Barre syndrome, primary diabetes mellitus, and some aspects of graft rejection.

International Patent Specification PCT/GB90/01169 discloses antigenic and/or immunoregulatory material derived from M. Vaccae for use in delaying or preventing the onset of 20 the AIDS syndrome.

Additionally, our unpublished International Patent Specification PCT/GB91/01970 discloses the use of M. vaccae in the treatment of uveitis, an immunologically mediated late consequence of leprosy, which causes blindness.

25 The present invention is based on the surprising observation that M. vaccae is also effective against a number of other conditions which may involve infections such as bacterial or protozoan infections and in particular mycobacterial infections.

It has been suggested that mental diseases such as schizophrenia and manic depression are associated with an autoimmune reaction resulting from past or on-going cryptic infection. Evidence for this is provided by abnormal B and T lymphocyte function such as increased B cells, decreased T cells and altered suppressor cell levels which have been observed in schizophrenia (see for example P. Sirota, Israel J. Med. Sci., 1990, 26, 694-697; J.G. Knight, Meth and Find Exptl Clin. Pharmacol., 1984, 64, 395-403; H.H. Fudenberg et al., Biomedicine & Pharmacotherapy, 1984, 38, 285-290; F. Villemain et al, Annal. N.Y. Acad. Sci., 1987, 496, 669-675; and Ganguli et al, Annal. N.Y. Acad. Sci., 1987, 496, 676-685). Evidence is also provided by the observation that schizophrenia and rheumatoid arthritis almost never occur in the same patient (T.D. Spector, J. Silman, Brit. J. Rheumatology, 1987, 26, 307-310). We believe that schizophrenia and rheumatoid arthritis may be caused by genetically determined, mutually exclusive, reactions to cryptic infection and probably mycobacterial infection. In a limited trial we have found that three out of three patients suffering from schizophrenia have shown a dramatic improvement when treated with M. vaccae. We therefore believe M. vaccae may be useful in treating mental diseases associated with an autoimmune reaction.

We have also found that M. vaccae is effective in the treatment of the immunologically mediated consequences of chronic infections.

Chaga's disease (South American Trypanosomiasis) is an example of a disease associated with a protozoan infection a late consequence of which is myocarditis which normally leads

to the death of a patient. Treatment with M. vaccae may reduce the incidence of myocarditis.

Another example of such disease is Takayasu's arteritis which is associated with tuberculosis which is caused by mycobacterial infection. It is believed that this and other vascular diseases including obstructive vascular diseases, which may be immunologically mediated, may be prevented and treated with M. vaccae.

It is also believed that M. vaccae may be effective in the prophylaxis and treatment of vascular complications associated with diabetes, which may be immunologically mediated.

10 The present invention accordingly provides a method for the prophylaxis or treatment of vascular diseases or vascular complications which are immunologically mediated, such as those associated with tuberculosis or diabetes, which method comprises administering to the patient suffering from such a condition an effective amount of therapeutic composition comprising antigenic and/or immunoregulatory material derived from Mycobacterium vaccae.

15 The invention further provides the use of antigenic and/or immunoregulatory material derived from M. vaccae in the manufacture of a therapeutic agent for the prophylaxis or treatment of vascular diseases or vascular complications which may be immunologically mediated, such as those associated with tuberculosis or diabetes.

20 The therapeutic agent of the invention conveniently, and therefore preferably, comprises dead cells of M. vaccae, most preferably cells which have been killed by autoclaving or by irradiation. The therapeutic agent normally comprises more than 10^6 microorganisms per ml of diluent, and preferably from 10^6 to 10^{11} killed M.



M. vaccae microorganisms per ml of diluent.

The diluent may be pyrogen-free saline for injection alone, or a borate buffer of pH 8.0. The diluent should be sterile. A suitable borate buffer is:

	Na ₂ B ₄ O ₇ ·10H ₂ O	3.63 g
5	H ₂ BO ₃	5.25 g
	NaCl	6.19 g
	Tween 80	0.0005%
	Distilled Water	to 1 litre

The preferred strain of M. vaccae is one denoted R877R isolated from mud samples from the Lango district of Central Uganda (J.L. Stanford and R.C. Paul, Ann. Soc. Belge Med. Trop. 1973, 53 141-389). The strain is a stable rough variant and belongs to the aurum sub-species. It can be identified as belonging to M. vaccae by biochemical and antigenic criteria (R. Bonicke, S.E. Juhasz, Zentralbl. Bakteriol. Parasitenkd.



Infection skr. Hyg. Abt. 1, Orig., 1964, 192, 133. The strain denoted R877R has been deposited under the Budapest Convention at the National Collection of Type Cultures (NCTC) Central Public Health Laboratory, Colindale Avenue, London NW9 5HT, 5 United Kingdom on February 13th, 1984 under the number NCTC 11659.

For the preparation of the therapeutic agent, the microorganism M. vaccae may be grown on a suitable solid medium. A modified Sauton's liquid medium is preferred (S.V. 10 Boyden and E. Sorkin., J. Immuno, 1955 75, 15) solidified with agar. Preferably the solid medium contains 1.3% agar. The medium inoculated with the microorganisms is incubated aerobically to enable growth of the microorganisms to take place, generally at 32°C for 28 days. The organisms are 15 harvested, then weighed and suspended in a diluent. The diluent may be unbuffered saline but is preferably borate-buffered and contains a surfactant such as Tween 80 as described above. The suspension is diluted to give 100mg of microorganism/ml. For further dilution, borate buffered saline 20 is preferably used so that the suspension contains 10 mg wet weight of microorganisms/ml in multidose vials. Although the microorganisms in the vials may be killed using irradiation e.g. from ⁶⁰ Cobalt at a dose of 2.5 megarads, or by any other means, for example chemically, it is preferred to kill the 25 microorganisms by autoclaving, for example at 15 psi (103.5 kPa) for 15 minutes (115°-125°C). It has been discovered that autoclaving yields a more effective preparation than irradiation.

The therapeutic agent is in general administered by

injection in a volume in the range 0.1-0.2 ml, preferably 0.1ml given intradermally. A single dosage will generally contain from 10^7 to 10^{10} killed M. vaccae microorganisms. It is preferred to administer to patients a single dose containing 5 10^8 to 10^9 killed M. vaccae. A single dose may be administered or the dose may be repeated depending on the condition of the patient.

Although the therapeutic agent will generally be administered by intradermal injection, other routes, e.g. oral 10 administration, can also be used.

It may be advantageous and is within the scope of the invention to use more than one strain of M. vaccae, and/or to include in the antigenic or immunoregulatory material other closely related mycobacterial species, such as M. 15 nonchromogenicum or M. chitae. Tuberculin may also be included.

The therapeutic agent can contain further ingredients such as adjuvants, preservatives, stabilisers etc. It may be supplied in sterile injectable liquid form or in sterile 20 freeze-dried form which is reconstituted prior to use.

M. vaccae may be used as such or an extract or fractioned portion of the organism to manufacture the therapeutic agents according to the invention.

The following Example illustrates the invention.

25

EXAMPLE

M. vaccae NCTC 11659 is grown on a solid medium comprising modified Sauton's medium solidified with 1.3% agar. The medium is inoculated with the microorganism and incubated for 28 days at 32°C to enable growth and maturation of the

- 8 -

microorganism to take place. The microorganisms are then harvested by gently scraping the surface of the agar and weighed (without drying) and suspended in M/15 borate buffered saline at pH8 to give 10 mg of microorganisms/ml of saline. 5 The suspension is dispensed into 5 ml vials, and then autoclaved for 15 minutes at 15 psi (103.5 kPa) to kill the microorganisms. After cooling, the therapeutic agent thus produced is stored at 4°C before use. A single dose consists of 0.1 ml of the suspension, which should be shaken vigorously 10 immediately before use, containing 1 mg wet weight of *M. vaccae*. The dose is given by intradermal injection normally over the left deltoid muscle.

EXAMPLE 2

15 The following Example demonstrates the effect of treatment with *M. vaccae* (MV) on the vascular aspects of leprosy. In particular, the bloodflow at the fingertips and the fingertips skin temperature is measured. It is clear from the study that leprosy patients receiving *M. vaccae* 20 immunotherapy were improved in the continuing vascular aspects of the disease.

1. The work consisted of laser Doppler flowmetry measurements of blood flow and skin temperature 25 measurements at the finger-pulp skin of leprosy patients. These parameters were measured in order to study the effect of MV immunotherapy on the impairment of peripheral circulation in leprosy patients.

2. The study was a blinded, randomised, placebo-controlled



- 9 -

study. Patients were randomised into two groups: one group had received *Mycobacterium vaccae* immunotherapy (a single intradermal injection of 0.1 ml (10^3 killed *M. vaccae*) and the other group saline (placebo) injections.

5 Both sets of patients had been treated eighteen months previously. The patients were allocated on a random basis (blind) and the data were gathered and analysed personally.

10 3. Leprosy patients often show a progressive deterioration in nerve function in the years following infection, with serious consequences such as ulcer formation of the lower limbs and progressive clawing of fingers.

15 Microcirculatory impairment complicates prognosis, especially in patients of long-standing, resulting in disproportionately cold fingers at high ambient temperatures.

4. Methods

20 At their first visit, 103 patient volunteers, all residents of Baba Baghi Leprosy Hospital, Tabriz, Iran, under the age of 65, were skin tested with 4 common mycobacterial antigens and the results recorded. These 25 patients were then randomly assigned to two groups. The first group (immunotherapy group, IT) were given one intradermal injection of 0.1 ml 10^3 killed *M. vaccae* and the second group (saline group, SAL) were given one 0.1 ml intradermal injection of saline.



- 10 -

5. At the second visit, 18 months after the first, 92 of these patients were still resident at the leprosy hospital and 84 (44 SAL, 40 IT) underwent repeat testing with the 4 common antigens. In addition, all 92 patients (45 SAL, 47 IT) had laser Doppler measurements of fingertip blood flow, vasomotor reflexes and finger sensation. All results were recorded by an operator who was unaware of the subject's IT or SAL status at the time of measurement. Since the measurements of blood flow and sensation could be done only at the second visit, 20 healthy subjects were chosen as controls; 10 were the adult offspring of treated leprosy patients and were residents at Baba Baghi Leprosy Hospital and 10 were apparently healthy members of the staff.
- 10
- 15
16. Measurement of blood flow by laser Doppler flowmetry (LDF)
- 20 The laser Doppler flowmeter (Perimed PF2, Perimed, Sweden) measures the movement of erythrocytes in the most superficial 1 mm of skin from changes in the frequency of coherent light reflected out of the tissue. The instrument is internally standardised and gives an integrated measurement of microvascular blood flow (LDFlux, expressed in Volts) which is related to the product of the number of moving erythrocytes and their mean velocity at the measurement site.
- 25
7. The fibre-optic tip was attached to the pulp of the distal phalanx by a probe holder fixed with double-sided



- 11 -

adhesive tape ensuring optimal alignment between sensor head and skin surface. The output signal was recorded continuously during the period of observation on a chart recorder (SE120, BBC Goetz, Metrawatt, Austria)

5 calibrated to a full scale deflection of 10V. The pulp of the finger was selected for investigation because its abundant arteriovenous anastomoses are under strict autonomic control.

10 8. Measurement of fingertip skin temperature.

A platinum skin thermistor attached to an LCD output device was used to measure skin surface temperature. The probe (Model 4098, 9 mm diameter, Yellow Springs

15 Instrument Co. Inc., Yellow Springs, Ohio, USA) was held in close contact with the skin with a single strip of Millipore adhesive tape. A stable temperature was generally achieved after 5 min contact with the skin of the pulp of the fingertip. The same sensor was used to measure atmospheric temperature near the subject during 20 the experimental procedure.

25 9. Experimental protocol.

Each subject was seated comfortably with the forearm and hand resting on a table at heart level at an ambient temperature of 25-29°C. This temperature was maintained by a large paraffin stove situated in the corner of the experimentation room. Ambient temperature was measured by a thermistor, described above, situated within 25 mm



- 12 -

of the subject at the same level as the hands. These conditions would be expected to induce near maximal peripheral vasodilation and a stable blood flow through the fingertips in healthy subjects. Each subject was allowed to equilibrate under these conditions for at least 15 min before measurements were started. All four fingers - index (2), middle(3), ring(4) and small (5) were studied on both the right and left hand under investigation. Skin temperature was first recorded, followed by LDFlux.

10. Statistical Analysis.

15 Differences between patient groups and control subjects for each measured parameter were assessed using Two-way ANOVA taking intra-individual differences between fingers into account.

11. Results.

20 The table which follows shows the effect of *M. vaccae* immunotherapy on LDFlux and fingertip skin temperature. The 95% confidence intervals for 20 healthy control subjects were 3.1-10.0 Volts for LDFlux (mean 6.6) and 31.0-35.0°C for skin temperature (mean 33.1°C). Consequently leprosy patient fingers with fingertip skin temperature measurements and LDFlux measurements of less than 31.0°C and 3.1 Volts respectively were considered impaired for that parameter.



- 13 -

12. LDFlux measurements and skin temperature were greater ($P<0.05$) in the IT group than the SAL and were lower in both groups ($P<0.05$) than in control subjects. In the SAL group 45.7% of all fingers had impaired LDFlux values (<3.1V) and 42.4% had impaired skin temperatures ($<31.0^{\circ}\text{C}$) whereas these values were 33.1 and 31.4% respectively for the IT group. In both groups the fourth and fifth fingers of each hand had lower LDFlux values than their respective counterparts in the healthy control group ($P<0.05$).
- 5
13. Comparing group results by disease classification, lepromatous patients undergoing IT had significantly higher LDFlux values than those undergoing SAL (Mean values 4.59 vs 3.91, representing 27% vs 42% impaired fingers respectively in each group). Tuberculoid patients showed a similar difference between IT and SAL groups but this did not reach a level of significance (mean values 4.06 vs 3.5). SAL subjects were found to have impaired temperature sensation compared with IT subjects.
- 15
- 20
- 25
14. The effect of *M.vaccae* immunotherapy (IT) or saline (SAL) administration on measurements of fingertip skin blood flow (LDFlux) and temperature.
- ...



- 14 -

	Control	BAL	IT
n (subjects)	20	45	47
n (fingers)	160	356	369
Room Temperature (°C)	25.2 (0.5)	25.1 (1.2)	25.3 (1.0)
Age (years)	31.5 (13.4) *	45.9 (9.3)	46.2 (12.5)
Residence at leprosy hospital (years)		22.1 (8.9)	22.7 (8.7)
LDFlux (V)	6.6 (1.7)	3.7 (2.8) *@	4.4 (2.7) *
Fingers in group with impaired LDFlux (%)	0.6	45.7 *@	33.1 *
Fingers in group with LDFlux <IV (%)	0	24.6 *	12.5 *
Fingertip skin temperature (°C)	33.1 (1.0)	30.4 (3.4) *@	31.0 (3.3) *
Fingers in group with impaired fingertip skin temperature (%)	3.8	42.4 *@	31.4 *

@ < immunotherapy group ($P<0.05$)* < Control ($P<0.05$) .

- 20 15. The results obtained demonstrated that those patients who had received *Mycobacterium vaccae* immunotherapy eighteen months previously had significantly higher mean laser Doppler flowmetry blood flows and higher mean skin temperatures in the finger-pulp than the corresponding control group.

EXAMPLE 3

25 This Example relates to treatment of a contact of a 30 leprosy patient who was found to have positive serological tests for *Trypanosoma cruzi*. Following treatment with *M. vaccae*, the patient was able to confer recognition of common mycobacterial antigens. *T. cruzi* infection has been



-15-

associated with a lack of response to such antigens.

1. A household contact of a leprosy patient attending the Hospital of Reconquista-Province of Santa Fe, was found to have positive serological tests for *Trypanosoma cruzi* (indirect immunofluorescence and indirect haemagglutination). This person did not respond to common mycobacterial antigens on skin testing with 4 intradermal injections of soluble mycobacterial reagents:
left forearm: tuberculin ($0.2\mu\text{gr}/0.1\text{ml}$)=10mm;
leprosin A ($1\mu\text{gr}/0.1\text{ml}$)=4mm; right forearm: scrofulin ($0.2\mu\text{gr}/0.1\text{ml}$)=0mm, vaccin($0.2\text{gr}/0.1\text{ml}$)=6mm.
2. A single injection of *Mycobacterium vaccae* was administered to the contact (10^6 heat-killed bacilli/ 0.1ml intradermally into the left deltoid area). It was found that the patient was skin-test positive to common mycobacterial antigens, on testing after a period of two years from receiving the injection of *M. vaccae*. Re-testing results were as follows: left forearm: tuberculin=8mm, leprosin A=10mm; right forearm: scrofulin=5mm, vaccin=15mm.
3. This single leprosy contact demonstrates that immunotherapy with *M. vaccae* was able to confer recognition of common mycobacterial antigens (as judged for the positive skin responses to the 4 antigens) despite the subject had serological evidence of *T. cruzi* infection, an infection that has been associated to a lack of response to this kind of antigen.



EXAMPLE 4

This Example describes a study carried out on the influence of *M. vaccae* on a rat model of chronic myocarditis (induced by *Trypanosoma cruzi*). It is demonstrated that the amount of damage done to the heart of the rats in the rat model of chronic myocarditis was significantly reduced following immunotherapy with killed *M. vaccae*.

10

1. A study on the influence of *Mycobacterium vaccae* has been carried out in a rat model of chronic myocarditis induced by *Trypanosoma cruzi*. Male "I" rats derived from a cross between *Rattus norvegicus* and eIMM rats were used. 21

15

day old rats were inoculated with 10^6 living trypomastigotes of a Tulahuen strain of *Trypanosoma cruzi*.

20

2. 30 days post-infection, two groups of infected rats were given an intracutaneous injection of 0.1 ml of immunotherapeutic agent and 8 infected rats received an injection of saline. The immunotherapeutic agent was a suspension of autoclaved *Mycobacterium vaccae* strain NCTC 11659 in borate buffered saline. The first group of 10

25

rats received an injection of 10^7 *M. vaccae*, the second group of rats (8) an injection of 10^7 *M. vaccae*, and a group of 8 received an injection of saline.

30

3. 180 days post-infection, the heart was removed from ether-killed rats. Hearts were cut in the transverse



plane, fixed in neutral formalin and embedded in paraffin wax. Sections were cut for microscopy, 5 μ m thick, and stained with haematoxilin and eosin, or Masson's trichome stain. Four sections of each heart were studied

5 carefully by a histopathologist experienced in pathology of the rat heart, blinded as to the experimental group from which the sections were derived. The degree of chronic myocarditis, defined by the presence of mononuclear cell infiltrate, myocyte degeneration of
10 necrosis, and fibrosis was classified according to the extent of lesions and numbers of affected muscle fibres, into small, medium and large foci. Analysis of fibrosis was made by comparing prevalence of foci showing fibrosis between the experimental groups.

15

4. The results were as follows:

Low dose of *M. vaccae* 76% of foci were small
12% of foci showed fibrosis

20

High dose of *M. vaccae* 57% of foci were small
30% showed fibrosis

Placebo group 58% of foci were small
52% showed fibrosis

25

The overall prevalence of fibrosis in rats receiving immunotherapy with 10⁷ *M. vaccae* was significantly less than in the placebo group P=0.011. Therefore, the amount of myocarditis was shown to be less for the group of rats receiving the lower dose of *M. vaccae* than in the placebo group, with the group receiving the larger dose of *M.*



- 18 -

vaccine occupying an intermediate position.

5. The study demonstrates that immunotherapy with 10^7 killed *Mycobacterium vaccineae* reduces the amount of damage done to hearts of the rat model of chronic myocarditis induced by *Trypanosoma cruzi*.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word 10 "comprise", and or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

15

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
259
260
261
262
263
264
265
266
267
268
269
269
270
271
272
273
274
275
276
277
278
279
279
280
281
282
283
284
285
286
287
288
289
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
309
310
311
312
313
314
315
316
317
318
319
319
320
321
322
323
324
325
326
327
328
329
329
330
331
332
333
334
335
336
337
338
339
339
340
341
342
343
344
345
346
347
348
349
349
350
351
352
353
354
355
356
357
358
359
359
360
361
362
363
364
365
366
367
368
369
369
370
371
372
373
374
375
376
377
378
379
379
380
381
382
383
384
385
386
387
388
389
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
409
410
411
412
413
414
415
416
417
418
419
419
420
421
422
423
424
425
426
427
428
429
429
430
431
432
433
434
435
436
437
438
439
439
440
441
442
443
444
445
446
447
448
449
449
450
451
452
453
454
455
456
457
458
459
459
460
461
462
463
464
465
466
467
468
469
469
470
471
472
473
474
475
476
477
478
479
479
480
481
482
483
484
485
486
487
488
489
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
509
510
511
512
513
514
515
516
517
518
519
519
520
521
522
523
524
525
526
527
528
529
529
530
531
532
533
534
535
536
537
538
539
539
540
541
542
543
544
545
546
547
548
549
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
18

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method for the prophylaxis or treatment of vascular diseases or vascular complications which are immunologically mediated, which method comprises administering to the patient suffering from such a condition an effective amount of antigenic and/or immunoregulatory material derived from *Mycobacterium vaccae*.
2. A method according to claim 1, wherein the antigenic and/or immunoregulatory material derived from *M. vaccae* comprises dead cells of *M. vaccae*.
3. A method according to claim 2, wherein the cells of *M. vaccae* have been killed by autoclaving.
4. A method according to any one of the preceding claims, wherein the material derived from *M. vaccae* is derived from the strain as deposited at the National Collection of Type Cultures (NCTC) Central Public Health Laboratory, Colindale Avenue, London, NW9 5HT, United Kingdom on February 13th, 1984 under the number NCTC 11659.
5. A method according to any one of the preceding claims, wherein each dose contains antigenic and/or immunoregulatory material in an amount of from 10^7 to 10^{10} *M. vaccae* microorganisms.
6. A product comprising antigenic and/or immunoregulatory



- 20 -

material derived from *Mycobacterium vaccae* when used in the prophylaxis or treatment of vascular diseases or vascular complications which are immunologically mediated.

7. A product according to claim 6, wherein the material derived from *M. vaccae* is as defined in any one of claims 2 to 5.
8. A product according to claim 6 or claim 7 which further comprises a pharmaceutically acceptable carrier or diluent.
9. Use of antigenic and/or immunoregulatory material derived from *Mycobacterium vaccae* in the manufacture of a therapeutic agent for the prophylaxis or treatment of vascular diseases or vascular complications which are immunologically mediated.
10. Use according to claim 9 wherein the antigenic and/or immunoregulatory material derived from *M. vaccae* comprises dead cells of *M. vaccae*.
11. Use according to claim 10 wherein the cells of *M. vaccae* have been killed by autoclaving.
12. Use according to any one of claims 9 to 11 wherein the material derived from *M. vaccae* is derived from the strain as deposited at the National Collection of Type Cultures (NCTC) Central Public Health Laboratory,



- 21 -

Colindale Avenue, London NW9 5HT, United Kingdom on
February 13th, 1984 under the number NCTC 11659.

13. Use according to any one of claims 9 to 12, wherein the therapeutic agent contains, per dose, antigenic and/or immunoregulatory material in an amount of from 10^7 to 10^{10} M. vaccae microorganisms.

Dated this 7th day of April 1999

University College London
By its Patent Attorneys
Davies Collison Cave



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.